Columns

Lupin Seeks EU Marketing Approval for YLB113, Etanercept Biosimilar, for Ankylosing Spondylitis

The European Medicines Agency has accepted for review Lupin‘s marketing authorization application for YLB113, a biosimilar of etanercept that is marketed by Amgen under the brand name Enbrel. YLB113’s application is for the treatment of ankylosing spondylitis, axial spondyloarthritis, and non-radiographic axial spondyloarthritis, as well as rheumatoid and psoriatic arthritis…

A Solid Foundation and Community Will Keep You Standing

Having a great foundation and support system is vital to the success of anything mighty you are trying to achieve. Being diagnosed with ankylosing spondylitis (AS) is no different. In fact, it is probably even more important to have a strong foundation of support and community. One of the main…

The New Year and the Journey Ahead

I think it’s safe to say, heading into the New Year, that we all have goals we plan to accomplish. I recommend letting the old things pass away and starting anew. Sure, we still will deal with doctor’s appointments and we still have ankylosing spondylitis (AS) or axial…